drugset
Drugs / Anti-Thymocyte Globin (ATG)
last change Jul 2019 re-read 3 minutes ago

Anti-Thymocyte Globin (ATG)

Protein / enzyme biologic

Developed for
type 1 diabetes mellitus
Investigated by
Genzyme, a Sanofi Company · The Leona M. and Harry B. Helmsley Charitable Trust · University of Florida

Trials 1

today NCT01106157 · Ph 1/2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01106157 Apr 2010 → Jan 2015 type 1 diabetes mellitus University of Florida Completed Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Anti-Thymocyte Globin (ATG) ClinicalTrials.gov intervention name — accepted as the source's own label NCT01106157 ↗
Modality Protein / enzyme biologic “anti-thymocyte globulin (ATG)” PMID 25500887 ↗ Dec 2014
Route Intravenous “ATG (2.5 mg/kg intravenously)” PMID 25500887 ↗ Dec 2014